Immunologic monitoring in breast cancer patients receiving postoperative adjuvant chemotherapy
✍ Scribed by Lars-Erik Strender; Henric Blomgren; Björn Petrini; Jerzy Wasserman; Marianne Forsgren; Renée Norberg; Edward Baral; Arne Wallgren
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 615 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## BACKGROUND. Amplification of certain genes is involved in resistance to chertiotherapy. The development of such amplification in patients by drug treatment has not yet been established. We have assessed the appearance of gene amplification in breast cancer patients with recurrent disease. One g
Serial plasma CEA levels were determined over a period of 1-3 years in 114 patients receiving adjuvant chemotherapy for T1, 2 or 3a N+ MO breast cancer. CEA values were correlated with clinical status, scintiscans, and other biochemical parameters. CEA values >2.5 ng/ml were considered abnormal. For
A retrospective study was done to evaluate the frequency and severity of wound complications in 112 patients with breast cancer who received adjuvant chemotherapy following mastectomy with immediate breast reconstruction. Data on wound complications were available for 120 mastectomies. The rate of c